F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comGujarat Themis Biosyn Ltd, a niche pharmaceutical company, is known for manufacturing bulk drugs and specialty chemicals for both domestic and international markets. The company’s focus on innovation, operational efficiency, and strong export potential has helped it maintain a steady performance in the stock market.
In this article, we’ll explore Gujarat Themis Biosyn’s share price targets from 2025 to 2030, along with its business highlights and investment insights.
Let’s begin by looking at Gujarat Themis Biosyn’s current market data.
| Detail | Value |
|---|---|
| Open | ₹348.40 |
| Previous Close | ₹350.70 |
| Volume | 46,432 |
| Value (Lacs) | ₹165.30 |
| VWAP | ₹353.52 |
| Beta (Volatility) | 2.23 |
| Market Capitalization | ₹3,879 Cr |
| Day's High | ₹362.00 |
| Day's Low | ₹346.80 |
| UC Limit | ₹420.80 |
| LC Limit | ₹280.60 |
| 52-Week High | ₹405.00 |
| 52-Week Low | ₹208.00 |
| Face Value | ₹1 |
| All-Time High | ₹405.00 |
| All-Time Low | ₹3.20 |
| 20D Avg Volume | 2,36,703 |
| 20D Avg Delivery (%) | 54.82% |
| Book Value Per Share | ₹20.51 |
| Dividend Yield | 0.19% |
Gujarat Themis Biosyn Ltd specializes in producing anti-tuberculosis drugs and other active pharmaceutical ingredients (APIs). The company has built strong relationships with both domestic buyers and export partners, ensuring consistent revenue streams.
It operates in a niche space of bulk drug manufacturing, giving it a competitive advantage in terms of cost structure and market demand stability.
Established reputation in anti-TB drug manufacturing
Strong export presence across multiple countries
Cost-effective production capabilities
Low debt levels and steady profitability
Strategic partnerships with leading pharma companies
| Investor Type | Holding (%) |
|---|---|
| Promoters | 70.86% |
| Retail & Others | 25.45% |
| Foreign Institutions | 2.51% |
| Mutual Funds | 1.16% |
| Other Domestic Institutions | 0.01% |
This high promoter holding reflects strong internal confidence in the company’s long-term growth potential.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 340 | 370 |
| 2026 | 380 | 420 |
| 2027 | 430 | 470 |
| 2028 | 480 | 520 |
| 2029 | 530 | 580 |
| 2030 | 590 | 650 |
These projections are based on Gujarat Themis Biosyn’s historical performance, industry growth rate, and overall pharmaceutical sector outlook.
By 2025, the company is expected to remain stable with moderate growth due to strong domestic and export demand for its APIs.
Why?
Stable anti-TB drug demand
Improved cost efficiency
Healthy promoter support
Investment Advice: Good for SIPs and staggered entries on dips.
Growth in exports and entry into newer API segments could boost revenue.
Why?
Increased API exports to emerging markets
Diversification into high-margin products
Investment Advice: Hold for long term; monitor quarterly growth.
Stronger profitability expected as the company leverages automation in manufacturing.
Why?
Operational efficiency improvements
Potential collaborations with global pharma majors
Investment Advice: Reinvest gains; maintain a long-term view.
By 2028, the company could cross the ₹500 mark comfortably.
Why?
Capacity expansion in Gujarat facilities
Sustained demand in both domestic and export markets
Investment Advice: Continue holding for compounding benefits.
Positioned as a niche leader in bulk drug manufacturing.
Why?
Consistent earnings growth
Expanding international client base
Investment Advice: Ideal for medium- to long-term investors.
By 2030, the company could achieve a strong global presence in the bulk drugs space.
Why?
Strategic alliances and product diversification
Low debt and strong balance sheet
Investment Advice: Strong candidate for wealth creation over the long term.
Yes, if you are looking for a niche pharmaceutical stock with consistent performance, Gujarat Themis Biosyn can be a solid addition to your portfolio.
Key Reasons to Invest:
High promoter holding (70.86%)
Strong API demand globally
Low debt and stable financials
⚠️ Risks to Watch Out For:
API price fluctuations
Regulatory changes in export markets
Competition from low-cost producers
Gujarat Themis Biosyn Ltd has shown steady growth over the years, backed by strong fundamentals and a focused business model. With its current price around ₹350.70 and strong demand outlook, analysts believe it could touch ₹650 by 2030.
For investors seeking steady compounding in the pharmaceutical space, Gujarat Themis Biosyn can be a potential long-term winner.
What is the current price of Gujarat Themis Biosyn?
As of August 12, 2025, it is ₹350.70.
What is the 52-week high and low of Gujarat Themis Biosyn?
52-week high: ₹405.00; 52-week low: ₹208.00.
Is Gujarat Themis Biosyn a good buy now?
If you believe in long-term pharma growth, it can be considered for staggered buying.
What is the promoter holding in Gujarat Themis Biosyn?
70.86% as of August 2025.
What is the target price for Gujarat Themis Biosyn in 2030?
Analysts project ₹590 – ₹650 by 2030.
Disclaimer: This article is for educational purposes only and not investment advice. Always consult a financial advisor before making stock market decisions.
Register & Login